A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid.
Sign Up to like & getrecommendations! Published in 2021 at "Bioconjugate chemistry"
DOI: 10.1021/acs.bioconjchem.1c00134
Abstract: Antibody-drug conjugates (ADCs) are complex pharmaceutical molecules that combine monoclonal antibodies with biologically active drugs through chemical linkers. ADCs are designed to specifically kill disease cells by utilizing the target specificity of antibodies and the… read more here.
Keywords: efficient method; cysteine; adcs; method ... See more keywords
Massive MIMO With Ternary ADCs
Sign Up to like & getrecommendations! Published in 2020 at "IEEE Signal Processing Letters"
DOI: 10.1109/lsp.2020.2967997
Abstract: Massive multiple-input-multiple-output (MIMO) system inevitably faces the hardware cost and energy efficiency problem due to its large number of antennas at the base station (BS). The use of low-resolution analog-to-digital converters (ADCs), e.g., typical 1-bit… read more here.
Keywords: adcs; bit adcs; massive mimo; ternary adcs ... See more keywords
The potential significance of alpha‐enolase (ENO1) in lung adenocarcinomas – A utility of the immunohistochemical expression in pathologic diagnosis
Sign Up to like & getrecommendations! Published in 2017 at "Pathology International"
DOI: 10.1111/pin.12607
Abstract: We herein analyzed the relationships among the immunohistochemical expression of alpha‐enolase (ENO1) and clinicopathological factors in order to define the significance of ENO1 in lung adenocarcinomas (ADCs). ENO1 expression was detected in most of the… read more here.
Keywords: enolase eno1; adcs; eno1; expression ... See more keywords
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004646
Abstract: Background Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs against solid tumors. This… read more here.
Keywords: gd2; drug conjugates; adcs; antibody drug ... See more keywords
Abstract 2186: Peptide-cleavable maytansinoid (ADCs) induce high bystander killing leading to improved anti-tumor activityin vivo
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-2186
Abstract: Antibodies targeting surface antigens on cancer cells typically have progressively lower access to tumor cells that are further removed from blood vessels. Also, the antibody will not bind to cells in the tumor mass that… read more here.
Keywords: adcs; maytansinoid adcs; cancer; bystander ... See more keywords
Abstract 982: Development of homogeneous dual-drug ADCs: Application to the co-delivery of auristatin payloads with complementary antitumor activities
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-982
Abstract: A common theme in treating cancer is the use of combination chemotherapy, where multiple drugs with different mechanisms of action are combined to elicit synergistic activity or overcome differential drug sensitivities. Antibody-drug conjugates (ADCs) have… read more here.
Keywords: auristatin; delivery; adcs; drug ... See more keywords
Abstract 737: Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit a favorable safety profile in cynomolgus monkey toxicology studies
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-737
Abstract: Background: Antibody Drug Conjugates (ADCs) target highly potent small molecule cytotoxic agents to tumors via tumor-specific antibodies. The therapeutic index of these drugs is strongly affected by a multitude of parameters, including -most importantly- (i)… read more here.
Keywords: immunity; adcs; antibody drug; toxicology ... See more keywords
Abstract 746: Development of novel formats of anti-AXL ADCs
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-746
Abstract: AXL is a member of the Tyro3- AXL -Mer (TAM) receptor tyrosine kinase subfamily which has been associated with several cellular functions including growth, migration, aggregation, and anti-inflammation (Li Y et al., 2009) via activation… read more here.
Keywords: axl; anti axl; adcs; cancer ... See more keywords
Abstract 1521: Unlocking the therapeutic index of highly potent site-specific ADCs in solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1521
Abstract: CD276 (B7-H3) is a transmembrane protein of the B7 family, which includes many prominent immune checkpoint targets, and is expected to play a role in T-cell stimulation, tumor-infiltration, as well as other tumorigenic functions with… read more here.
Keywords: adcs solid; therapeutic index; solid tumors; adcs ... See more keywords
Abstract 3242: Efficacy evaluation by novel humanized mouse models for preclinical study of ADCs combined with immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3242
Abstract: Antibody-drug conjugates (ADCs) are effective anti-tumor therapies with high specificity, with little toxicity and side effects. Xenograft tumor models based on immunodeficient mice have been used for evaluating the human anti-tumor efficacy of ADCs. However,… read more here.
Keywords: humanized mouse; efficacy; adcs; tumor ... See more keywords